

BLONDER TONGUE LABORATORIES INC

Form 8-K

March 23, 2015

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

Current Report Pursuant to Section 13 or 15(d) of  
the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): March 19, 2015

Blonder Tongue Laboratories, Inc.

(Exact Name of registrant as specified in its charter)

Delaware

(State or other jurisdiction of  
incorporation)

1-14120

(Commission File Number)

52-1611421

(I.R.S. Employer Identification  
No.)

One Jake Brown Road, Old Bridge, New Jersey 08857

(Address of principal executive offices) (Zip Code)

Registrant's telephone number, including area code: (732) 679-4000

Not Applicable

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))



ITEM 1.01. ENTRY INTO A MATERIAL DEFINITIVE AGREEMENT

Director Stock Purchase Plan

On March 19, 2015, the Board of Directors of Blonder Tongue Laboratories, Inc. (the “Company”) adopted the Director Stock Purchase Plan (the “Plan”). The Plan allows non-employee directors of the Company to elect to purchase common stock of the Company in lieu of receiving a portion (up to 65%) of their annual director retainer fee. The maximum number of shares of common stock that can be purchased by all participants, in the aggregate, pursuant to the Plan is 150,000 shares. The shares will be purchased directly from the Company at the fair market value of the Company’s common stock on the date of purchase (based on selling prices reported on NYSE MKT), which is the date on which a quarterly installment of the director retainer fee is paid by the Company to its non-employee directors.

The foregoing summary is not complete and is qualified in its entirety by reference to the Plan, which is filed as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference.

ITEM 9.01 FINANCIAL STATEMENTS AND EXHIBITS

(d) The following exhibit is filed herewith:

Exhibit 99.1 Director Stock Purchase Plan

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

BLONDER TONGUE LABORATORIES, INC.

/s/ Eric Skolnik

By: Eric Skolnik  
Senior Vice President and  
Chief Financial Officer  
Date: March 23, 2015